Dyadic International (DYAI) Share-based Compensation Growth (1y) (2019 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Share-based Compensation Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.78 Bn | 192.79 Bn | 7.24 Bn | 19.90% |
| 2 | Gilead Sciences | 179.92 Bn | 176.74 Bn | 6.22 Bn | 2.67% |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | 71.86% |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | -3.46% |
| 5 | Argenx Se | 60.35 Bn | 55.17 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | -7.69% |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | -22.43% |
| 8 | Biogen | 31.92 Bn | 30.63 Bn | 1.96 Bn | 3.34% |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 17.65 Mn | 9.69 Mn | - | -10.61% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -10.61% |
| Dec 31, 2025 | -30.01% |
| Sep 30, 2025 | 1.49% |
| Jun 30, 2025 | 2.91% |
| Mar 31, 2025 | 6.69% |
| Dec 31, 2024 | -7.74% |
| Sep 30, 2024 | 6.36% |
| Jun 30, 2024 | 6.85% |
| Mar 31, 2024 | 9.05% |
| Dec 31, 2023 | -38.04% |
| Sep 30, 2023 | 4.06% |
| Jun 30, 2023 | -0.79% |
| Mar 31, 2023 | -0.11% |
| Dec 31, 2022 | 4.58% |
| Sep 30, 2022 | 9.47% |
| Jun 30, 2022 | 14.60% |
| Mar 31, 2022 | -98.71% |
| Dec 31, 2021 | 18.58% |
| Sep 30, 2021 | 1,104.00% |
| Jun 30, 2021 | 999.19% |